Initially created to address Type 2 diabetes, GLP-1 medications revealed an unexpected benefit: substantial weight loss. This discovery spurred additional research and led to FDA approval for their use in managing obesity and overweight conditions under the names Ozempic (as Wegovy) and Mounjaro (as Zepbound). These drugs contain the active ingredients Semaglutide and Tirzepatide.

​

Administered primarily via injections with small needles placed in fatty tissue, these medications interact with cell receptors in the pancreas, gastrointestinal tract, and other areas. They are engineered to mimic peptide molecules naturally produced in the body. By slowing down the digestion process and the rate at which food exits the stomach, these drugs induce a sense of prolonged fullness after meals. Additionally, they affect brain regions involved in craving control, helping to manage stress-eating and reward-related eating habits, which contributes to weight loss.